Summer Sale

Up to 30% off — ends 7 Aug

ONLY00h00m00s

Get 30% Off

Up to 30% off — ends 7 Aug

ONLY00h00m00s

William Dalton

Johns Hopkins University

United States

This profile is automatically generated from trusted academic sources.

Google Scholar

ORCID

How do I reach out?

Meet Kite AI

Contact this professor

ORCID

Google Scholar

Research Interests

Cell Biology

70%

Immunology

20%

Hematology

60%

Cancer Genetics

50%

Hematopoiesis

40%

Genomic Instability

30%

Stem Cell Transplantation

30%

Ask ApplyKite AI

Start chatting

How can you help me contact this professor?

What are this professor's research interests?

How should I write an email to this professor?

Articles16

Intensive chemotherapy vs venetoclax/hypomethylating agents for patients aged 60 to 75 years with favorable, NPM1-mutated AML

Article Link

Year:

2025

The E592K variant of SF3B1 creates unique RNA missplicing and associates with high-risk MDS without ring sideroblasts

Article Link

Year:

2024

Outcome heterogeneity of <i>TP53</i>-mutated myeloid neoplasms and the role of allogeneic hematopoietic cell transplantation.

Article Link

Year:

2024

An accessible patient-derived xenograft model of low-risk myelodysplastic syndromes

Article Link

Year:

2024

Tumor-derived CCL2 drives tumor growth and immunosuppression in IDH1-mutant cholangiocarcinoma

Article Link

Year:

2024

Allogeneic Blood or Marrow Transplantation with High-Dose Post-Transplantation Cyclophosphamide for Acute Lymphoblastic Leukemia in Patients Age ≥55 Years

Article Link

Year:

2023

Co-occurring mutations in ASXL1, SRSF2, and SETBP1 define a subset of myelodysplastic/ myeloproliferative neoplasm with neutrophilia

Article Link

Year:

2023

Venetoclax in combination with hypomethylating agent for the treatment of advanced myeloproliferative neoplasms and acute myeloid leukemia with extramedullary disease

Article Link

Year:

2023

CCRL2 affects the sensitivity of myelodysplastic syndrome and secondary acute myeloid leukemia cells to azacitidine.

Article Link

Year:

2022

Genomic landscape of myelodysplastic/myeloproliferative neoplasm can predict response to hypomethylating agent therapy

Article Link

Year:

2022

Nonmyeloablative Allogeneic Transplantation With Post-Transplant Cyclophosphamide for Acute Myeloid Leukemia With IDH Mutations: A Single Center Experience

Article Link

Year:

2022

Taking the STING out of acute myeloid leukemia through macrophage-mediated phagocytosis

Article Link

Year:

2022

How low risk are low risk myelodysplastic syndromes?

Article Link

Year:

2022

Cell-specific regulation of gene expression using splicing-dependent frameshifting

Article Link

Year:

2022

The metabolic reprogramming and vulnerability of SF3B1 mutations

Article Link

Year:

2020

The K666N mutation in SF3B1 is associated with increased progression of MDS and distinct RNA splicing

Article Link

Year:

2020

Collaborators11

Minzhong Yu

University Hospital

UNITED STATES

Lukasz P Gondek

Johns Hopkins University

UNITED STATES

Challice Bonifant

Assistant Professor

Johns Hopkins University School of Medicine

UNITED STATES

Jonathan Ling

Assistant Professor

Johns Hopkins University School of Medicine

UNITED STATES

Saurav Haldar

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES

Céline Philippe

Université de Reims

FRANCE

Tania Jain

UNITED STATES

Kevin Rouault-Pierre

Senior Lecturer

Barts Cancer Institute

UNITED KINGDOM

Saumya Maru

Assistant Professor

Fox Chase Cancer Center

UNITED STATES

Riley Bergman

Vanderbilt University

UNITED STATES

Alexander J. Ambinder

Johns Hopkins University School of Medicine

UNITED STATES

How do I reach out?

Meet Kite AI